Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Well it’s clear to me she is specifically allowing the Market cap to fall to allow a chunk to be sold at a significantly discounted rate. And realistically after the first duster anyone coming in now will want one heck of a premium. Catch a falling knife ? Could be a penny who knows?
Problem that mere investors here have is we don’t really know the full picture, we are totally in the dark. Nobody will chuck cash at this if the chances of extracting Helium are zero. So can we assume if cash is invested they expect the second spud to deliver?
Well VAL have delivered exactly ZERO revenue in 15 years excepting a three month lab contract so there is zero chance of a NASDAQ listing on revenue exclusion not to mention the costs involved in a duel listing. Not viable.
Back on planet reality, they need to prove the current model and get finances sorted. I genuinely don’t see how the business challenges they face can be resolved with the current BOD. It will be interesting to see what support the board secures at next years AGM especially once they resolve the current financial position.
@OB - see I didn’t mention the incoming placing in this message - opps, take care
@Betterlife
1. If you buy a selection of AIM shares a high number of them will go south and a small number deliver high returns, Top slicing will help reduce losses. Likewise selling half should the SP double so you are in for free.
2. Adam has his reasons for investing and supporting the BOD that’s his business I’m not in anyway trying to compete so not sure I understand your question.
@PatientInvestor
Can you please define for me how “401 is done” please? My understanding is it went to the new 1 yr old Phoenix company Ambrose for them to try and position over the next year and they have an “option” if they can then find a partner or investor to fund trials. Ambrose raised £500k for their own business they are certainly not in a position to fund a £20m phased trial.
Further, my perspective was that it was VAL that took the ideas from University dev and they did the positioning part to then secure a license fee and forward licensing agreement with bigger bio that can afford to fund trials to the next stage.
Why can’t VAL do what Ambrose can? Do we lack the skill sets? But whatever the case I don’t consider a promise note of a 12mth “Option” and an undeclared token share issue in an illiquid share to be a great “done deal” outcome but each to their own.
Great post paternostpauper, NO PLACING!, IT'S JUST NOT HAPPENING. Great post paternostpauper, Great post paternostpauper, oh feel so much better now, you are so right, no placing thank goodness for that... amazing post, just amazing.
Just listen to yourselves, posting same old same old confirmation bias nonsense and championing the posters that confirm same, and removing posts you don't like, its ridiculous.
Look, Suzy is running a business here. A business with a limited remaining cash runway. She has confirmed same but you refuse to accept it. What do you expect her to do?
It is clear as day that she will need to organise a placing shortly and i would say that based on the last couple of trading days some in the inner circle already know this is going to happen.
How else can she get actual cash into the business? It is clear to me she was hopeful that THX would pay her to stave off the placing but is that realistic? Its the 11th on Monday? there simply isn't enough time.
Even if THX and EUDA merge the chances of the new shell having cash are zero, even with Heads of Terms it would take a while to complete then they need to go on and raise. It s total fantasy to think THX can now transfer cash to VAL in the remaining time left, its not realistic but please just keep burying your heads in the sand and stick fingers in your ears whilst singing lar lar lar its safer.
I respect this is not what the perma bulls here want to read and will probably request removal of my post but ignoring the facts of the situation doesn't change them. See you at the placing at 4p or 2p if Turner Pope cant secure support - it is what it is.
How many times have you seen this play out??? come on....
@PatientInvestor
LMOL, now I am genuinely laughing at you
So it’s now “Super Stella” the same Stella that won’t buy any shares in this business and on explaining why she won’t touch them delivered what was dubbed at the time her “Gerald Ratner” moment only a few weeks back, the same Stella that you were calling to be removed from the board at the AGM now she’s “Super Stella”.
You really are a prize, amazing
@TDK
Yes, far more experience of that specific company than me. I can see a lot of the business mistakes but hold my hand up if there are elements of a business i am unclear of. In relation to PYC i can tell you that @Share4 knows his stuff and some of the renamed/ reinvented poster that sit on that forum board 24/7 ramping the back end out of it and policing its content just like some of the suspects over here.
We should all be here to share information not work against each other and not create a ramping echo chamber. Its hard enough in these markets to hold the feet to the fires of some of the directors of some of these penny share plays as it is!!
@TDK
FYI, it was actually me that started commenting on PYC which the poster @Share4 has far more historic experience of then i do. The whole point of these boards should be to exchange views on a stock and its performance for new investor evaluations. Not to act as a echo chamber for posters like you to feel better about their investment choices.
@PM2022
So I’m a fool am I because I point out the bleeding obvious?
Because I believe it’s manipulation in an attempt to hype up the SP simply to try and get the placing away at a better price.
None of any of this will result in cash coming in other than from a shareholder placing.its a total farce. It’s like the THX LOI presented slightly differently for the BOD to continue feeding a lifestyle at shareholders expense.
My mention of the cash runway is because I consider it material here. IF no runway left to meet payroll and other costs in Jan which is what the financials declared point to how else can they trade without yet another placing. It’s kind of a massive elephant in the room imo and the telegram ramping crew removing messages over on LSE that explore this is absolutely ridiculous.
Suzy has to grant 14 days notice for EGM and resolutions. So we are now, 5th Dec, at a critical point where Suzy needs to be as bullish as possible for her life so this SP holds up to get that placing away.
Surely you can see this?
@PatientInvestor
Many a true word said in jest!!
You may well get an invite to join Suzy and Kevin by zoom on a live call in a couple of weeks time. It wont be the 15th though as they have to give 14 days clear notice of an EGM and it wont be for drinks and fun times but you don't need me to spell it out.
Be careful what you wish for.....
I agree that over at Beyond Blood their prototype hand held blood testing machine could well ultimately benefit patients with Neutropenia allowing for home test rather than visiting the hospital. There are lots of rare diseases that need better ways to manage the condition. You might be better off dumping your PYC shares and investing in the Beyond Blood Business if you are passionate about home testing?
This rare disease affects circa one in a million people, so it’s a small U.K. number 65? but a bigger Stateside one 35m:-
https://www.raredisease.org.uk/rduk-news/one-in-a-million-cyclical-neutropenia/
You would think Abbott’s and the big US hand held testing players would be doing this but maybe market size too small for it to be economically viable. If over the next few years Beyond Blood can perfect the tool maybe they could approach someone like abbots then to manufacture on a royalty who knows. But that’s over at Beyond Blood.
Meanwhile here at PYC Jim’s first job is to get consultancy fees exceeding overheads, get to break even, otherwise until then II will continue to avoid and just consider it a lifestyle business forever raising cash just to trade.
@Riddler
He earns decent money, you know that, over the last six years he has drawn the best part of almost a million quid out the company, so it’s a decent lifestyle he gets from PYC he is not some under paid hard done to worker!
It’s down to investor ROI now, what value we get? At the moment it’s down to if they grasp the concept of a business needing to deliver growth and more importantly profits or not. It will take time and probably more investor cash but the Jury is out if they grasp the concept - to date they have proven they don’t.
They have never made a profit since they listed and based on the last sets of results revenues have gone backwards. Anyhow, let’s see what they do.
Bless you too
I can't imagine there being much now to report on until early March when we see what the H1 trading figures to end of Dec 23 look like. So this is a period for them to get their heads down and prove they can deliver and get this business to break even.
Myself, i can't see them reaching Break even in this financial year. In addition to trying to secure more contracts they need to get the diversification into Biostats going but the appointment of Dr Venkata Putcha, as Head of Biostatistics only happened recently and i bet he's a 100k+ appointment so if anything we will see the cost base increase further before we see revenues adding from Biostats and this will take time to establish. Two months in the job to the end of H1 wont be long enough and i suspect he would need longer than the H2 period, even hitting the ground running, before he can turn in a profit from Biostats work.
Meanwhile, the simply wall street news article i don't think will have helped the share price either. The share price adjustment yesterday could be a rebound from that article now that all AGM resolutions have been confirmed as passed at the end of last week and there was no kick back to the salary levels being paid on the previous poor financial performance:-
https://uk.finance.yahoo.com/news/shareholders-may-object-pay-rise-050424361.html
So in all, this looks like a period now for them to prove they can turn this around but its going to take time as i see it and past track record hasn't been great has it.
GLA
Closed -10.6% down and that was following yesterday's-3% down close.
I don't consider suzy,s basic salary of £160k to be low, frankly its significantly higher than many of the posters here risking their hard earned cash on the shares the board refuse to purchase.
@Aberystwyth
For clarity: PYC is a consulting business, as such it earns consultancy fees for modelling in respect of set period projects. Hence why every year they have high client churn with projects finishing and have to fight hard to win new ones just to stand still.
It’s a long hard journey not made any easier against the sector back drop when reductions in biotech spending are a necessity to survive and external consultancy fees are the first on the list to chop or put on hold.
It is what it is
@Semantic
I'm in total agreement
This is why it’s getting harder to raise cash on the AIM, why we have the current biotech funding drought and why when many come back multiple times for more working capital raises the discounts have to be brutal. As you say you can now get over 5% on deposited sums with no risk to the capital whatsoever.
Crazy situation with some of these lifestyle companies that list on the AIM.
I mean, if you had say a small business, registered as a limited company that you started up with your own cash, friends and family perhaps even a bank loan and it was losing money EVERY year, would you still carry on with it?
But moreover, let’s say you thought ok, I’m going to run with this, borrow more cash to keep trading and you did £600k of sales but lost another £500k in doing so, would you go on again and repeat the same for the following year? In addition would you pay yourself £140k knowing the business can’t afford it or would you take a pay cut and reduce costs to get some balance?
This is the situation isn’t it, I’m fast of the opinion that in many cases being on the AIM means you can chuck basic business commercial acumen out the window and do what the fudge you like because as long as investors chuck cash at you, there is no need to illustrate any need to try and make a profit, just take what the hell you like?
It goes unchallenged?
The ramping here just like over at VAL is off the scale again!!! Give it a rest @Riddler
Look, forget acquisitions and magical money pots landing, its dead simple:-
Jim just needs to build out the mathematical modelling side, try and get the biostats new side going to add to revenues and work to reach the break even point.
IF Jim can get to break even he doesn't need anything else, the rest including the share price will take care of itself. He has a window to do that. Burning question is can he do it?
Most likely, he will need another raise Q1 2024 and the back history has not been great. but the business as it stands cant continue forever making losses. This next 18mth will be fairly key for the business IMO.
See how it goes.
@HD
I read the boards and agreed to step out short term. My intention has never been to upset anyone it’s been merely to debate an alternative view.
You meanwhile are “emotionally” invested and not thinking commercially, that’s your business
But if you want to keep disrespecting me because I have a different opinion on events, I’m quite happy to rejoin the debate here and give my opinion.
So in the nicest possible way stop with the insults.
@Sniper88
Exactly
Other issue is that its not like they can crack on at the second drill location as still awaiting drill repairs. So could still be a few weeks before they can start it.
If they are trying to raise yet again it will be brutal, they need to raise from positions of strength NOT weakness